Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bio-Imaging Technologies Raises $10.8 Million in Private Placement.


Business Editors

NEWTOWN, Pa.--(BUSINESS WIRE)--Sept. 16, 2003

Bio-Imaging Technologies, Inc. (AMEX AMEX

See: American Stock Exchange
: BIT) announced today that the Company has entered into definitive agreements with certain institutional investors Institutional Investor

A non-bank person or organization that trades securities in large enough share quantities or dollar amounts that they qualify for preferential treatment and lower commissions.
 in connection with a private placement of the Company's Common Stock, raising gross proceeds to the Company of approximately $10.8 million.

Bio-Imaging has agreed to sell an aggregate of 1,762,000 shares of Common Stock at $6.125 per share.

The proceeds of the financing are expected to be used for general corporate purposes, including working capital and capital expenditures, and for possible acquisitions.

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  in the absence of an effective registration statement or exemption from registration requirements. The Company has agreed to file a resale resale n. selling again, particularly at retail. In many states a "resale license" or "resale number" is required so that the state can monitor the collection of sales tax on retail sales.


RESALE.
 registration statement on Form S-3 within 30 days after the closing of the transaction for purposes of registering the shares of Common Stock acquired by these investors.

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized spe·cial·ize  
v. spe·cial·ized, spe·cial·iz·ing, spe·cial·iz·es

v.intr.
1. To pursue a special activity, occupation, or field of study.

2.
 in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab (Newtown PA), European Core Lab (Leiden, The Netherlands) and U.S. Business Offices (Massachusetts and California).

Certain matters discussed in this press release are "forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
" intended to qualify for the safe harbors Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 from liability established by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance Circumstance or circumstances can refer to:
  • Legal terms:
  • Aggravating circumstances
  • Attendant circumstance
.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 16, 2003
Words:435
Previous Article:S&P Asgns Prlim Rtgs in Bankinter's Spanish RMBS Deal.
Next Article:Aelita Enterprise Directory Manager Wins Windows & .NET Magazine Readers' Choice Award; Aelita Product Named Best User and Directory Management Tool.
Topics:



Related Articles
MEDITECH/ELAN BIO VENTURE TO DEVELOP DISEASE SCANNERS.
Bio-Imaging Technologies' Third Quarter Service Revenue Rises 25%; Operating Margin Continues to Improve.
Bio-Imaging Technologies to Release Year-End Results and Host Conference Call on February 4, 2004.
Bio-Imaging Technologies to Release Fourth Quarter and 2005 Year End Financial Results and Host Conference Call on February 22, 2006.
Fujifilm to Make Full Entry into Antibody Therapeutics Market.
Mentored Quantitative Research Development Award (K25).
Bio-Imaging Technologies to Release First Quarter 2006 Financial Results and Host Conference Call on May 3, 2006.
Bio-Imaging Technologies to Release Second Quarter 2006 Financial Results and Host Conference Call on August 2, 2006.
Bio-Imaging Technologies to Release First Quarter 2007 Financial Results and Host Conference Call on May 2, 2007.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles